
    
      The study will be conducted in two parts:

      Part 1: Open-label dose-finding study of irinotecan liposome injection. 30 patients were
      enrolled.

      Part 1 Primary Objectives:

        -  Describe the safety and tolerability of irinotecan liposome injection monotherapy
           administered every 2 weeks

        -  Determine the optimal irinotecan liposome injection monotherapy dose for Part 2 of this
           study

      Part 2: A randomized, efficacy study of irinotecan liposome injection versus IV topotecan.

      Approximately 450 patients will be enrolled in part 2.

      Part 2 objectives: Detailed in the Primary & Secondary outcome measure sections.
    
  